A pilot clinical trial with the iron chelator Deferiprone in Parkinson's disease - Pilot clinical trial iron chelator Deferiprone in Parkinson's Vs1

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-001148-31-GB

Enrollment

Registered

2011-08-17

Start date

2011-09-13

Completion date

Unknown

Last updated

2019-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Trade Name: Ferrprox (Deferiprone) Product Name: Deferiprone (Ferriprox) Pharmaceutical Form: Oral liquid INN or Proposed INN: Deferiprone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients will have a diagnosis of clinical idiopathic Parkinson’s disease (UK PDS Brain Bank diagnostic criteria) disease duration =65 years) yes F.1.3.1 Number of subjects for this age range 24

Exclusion criteria

Exclusion criteria: Patients with other neurological conditions, psychiatric disorders and history of depression will be excluded as will patients with a history of diabetes, renal or liver disease, blood disorders, immune compromised, history of agranulocytosis, or condition contraindicatory for MRI examination e.g pacemaker. Outside age bracket

Design outcomes

Primary

Measure	Time frame
Primary end point(s): The primary outcome measure is the in vivo assessment of whether Deferiprone can remove excess brain iron in the substantia nigra of Parkinson's disease patients as assessed by MRI imaging without major side effects of drug treatment.;Main Objective: To assess whether 6 month treatment with Deferiprone is well tolerated by PD patients and assess whether such treatment removes excess iron in the brain area affected in PD, the substantia nigra, as assessed by MRI.;Secondary Objective: Assess whether Deferiprone therapy directly affects the symptoms of Parkinson's disease or other brain function e.g. psychological well being, during the course of the 6 months trial period.	—

Measure

Time frame

Primary end point(s): The primary outcome measure is the in vivo assessment of whether Deferiprone can remove excess brain iron in the substantia nigra of Parkinson's disease patients as assessed by MRI imaging without major side effects of drug treatment.;Main Objective: To assess whether 6 month treatment with Deferiprone is well tolerated by PD patients and assess whether such treatment removes excess iron in the brain area affected in PD, the substantia nigra, as assessed by MRI.;Secondary Objective: Assess whether Deferiprone therapy directly affects the symptoms of Parkinson's disease or other brain function e.g. psychological well being, during the course of the 6 months trial period.

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026